Retrospective analysis of the safety and efficacy of vandetanib as systemic treatment for patients with advanced and progressive medullary thyroid cancer (MTC)

被引：0
|
作者：
Capdevila, Jaume
Martinez-Trufero, Javier
Dalmau, Elsa
Alvarez-Escala, Cristina
Beltran, Miguel
Duran, Manuel
Gallegos, Isabel
Luis Manzano, Jose
Mesla, Ricard
Pajares, Isabel
Fuentes Pradera, Jose
Grau, Juan J.
Reig, Oscar
Manuel Trigo, Jose
Grande, Enrique
机构：
[1] Vall dHebron Univ Hosp, Barcelona, Spain
[2] Hosp Miguel Servet, Zaragoza, Spain
[3] Univ Autonoma Barcelona, Corp Sanitaria Univ Parc Tauli, Sabadell, Spain
[4] La Paz Univ Hosp, Dept Endocrinol, Madrid, Spain
[5] Hosp Univ Josep Trueta, Inst Catala Oncol, Girona, Spain
[6] Rey Juan Carlos Univ Hosp, Madrid, Spain
[7] Hosp Gen Segovia, Segovia, Spain
[8] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain
[9] Catalan Inst Oncol, Barcelona, Spain
[10] Hosp Univ Miguel Servet, Zaragoza, Spain
[11] Hosp Univ Virgen de Valme, Seville, Spain
[12] Hosp Clin Barcelona, Barcelona, Spain
[13] Hosp Univ Virgen de la Victoria, Malaga, Spain
[14] Hosp Univ Ramon y Cajal, Dept Med Oncol, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17016
引用
收藏
页数：1
相关论文
共 50 条
  • [1] SAFETY AND EFFICACY OF VANDETANIB AS SYSTEMIC TREATMENT FOR PATIENTS WITH ADVANCED AND PROGRESSIVE MEDULLARY THYROID CANCER (MTC)
    Grande, E.
    Martinez-Trufero, J.
    Arevalo, S.
    Alvarez-Escola, C.
    Beltran, M.
    Jimenez Fonseca, P.
    Alonso-Gordoa, T.
    Dalmau, E.
    Duran, M.
    Gallegos, I.
    Manzano, J. L.
    Mesia, R.
    Pajares, I.
    Fuentes, J.
    Grau, J. J.
    Reig Torras, O.
    Trigo, J. M.
    Pelaez, B.
    Zafon, C.
    Capdevila, J.
    ANNALS OF ONCOLOGY, 2014, 25
  • [2] Efficacy and safety of vandetanib for patients with advanced and progressive medullary thyroid cancer (MTC) as systemic treatment beyond first-line therapy
    Hernando Cubero, J.
    Grande, E.
    Jimenez Fonseca, P.
    Villabona, C.
    Trigo Perez, J. M.
    Martinez Trufero, J.
    Pajares Bernad, I.
    Lopez, C.
    Alonso, T.
    Biarnes, J.
    Ramon y Cajal, T.
    Duran, M.
    Grau, J. J.
    Arevalo Lobera, S.
    Mesia Nin, R.
    Llanos, M.
    Dalmau Portulas, E.
    Alvarez, C.
    Zafon, C.
    Capdevila, J.
    ANNALS OF ONCOLOGY, 2018, 29 : 476 - 476
  • [3] The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer
    Fallahi, Poupak
    Ferrari, Silvia Martina
    Baldini, Enke
    Biricotti, Marco
    Ulisse, Salvatore
    Materazzi, Gabriele
    Miccoli, Paolo
    Antonelli, Alessandro
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (11) : 1109 - 1118
  • [4] AN INDIRECT TREATMENT COMPARISON OF CABOZANTINIB VERSE VANDETANIB IN PROGRESSIVE MEDULLARY THYROID CANCER (MTC)
    Rinciog, C.
    Myren, K. J.
    Alden, M.
    Diamantopoulos, A.
    LeReun, C.
    VALUE IN HEALTH, 2014, 17 (07) : A616 - A616
  • [5] Meta-Analysis of the Efficacy and Safety Evaluation of Vandetanib in the Treatment of Medullary Thyroid Cancer
    Xian, Tong-cheng
    Yang, Min-ye
    Zhang, Xue-lin
    Wang, Jie
    Luo, Yi
    HORMONE AND METABOLIC RESEARCH, 2024, 56 (09) : 649 - 653
  • [6] Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer
    Hu, Mimi I.
    Elisei, Rossella
    Dedecjus, Marek
    Popovtzer, Aron
    Druce, Maralyn
    Kapiteijn, Ellen
    Pacini, Furio
    Locati, Laura
    Krajewska, Jolanta
    Weiss, Richard
    Gagel, Robert F.
    ENDOCRINE-RELATED CANCER, 2019, 26 (02) : 241 - 250
  • [7] Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer
    Deshpande, Hari
    Marler, Vicky
    Sosa, Julie Ann
    ONCOTARGETS AND THERAPY, 2011, 4 : 209 - 215
  • [8] Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer
    Koehler, Viktoria F.
    Adam, Pia
    Frank-Raue, Karin
    Raue, Friedhelm
    Berg, Elke
    Hoster, Eva
    Allelein, Stephanie
    Schott, Matthias
    Kroiss, Matthias
    Spitzweg, Christine
    THYROID, 2021, 31 (03) : 459 - 469
  • [9] Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial
    Kreissl, Michael C.
    Bastholt, Lars
    Elisei, Rossella
    Haddad, Robert
    Hauch, Ole
    Robinson, Bruce
    Colzani, Raffaella
    Foster, Meredith
    Weiss, Richard
    Schlumberger, Martin
    Jarz, Barbara
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (24) : 2773 - +
  • [10] Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis
    de Castroneves, Luciana Audi
    Negrao, Marcelo Vailati
    Costa de Freitas, Ricardo Miguel
    Papadia, Carla
    Lima, Jose Viana, Jr.
    Fukushima, Julia T.
    Simao, Eduardo Furquim
    Vamondes Kulcsar, Marco Aurelio
    Tavares, Marcos Roberto
    de Lima Jorge, Alexander Augusto
    de Castro, Gilberto
    Hoff, Paulo Marcelo
    Hoff, Ana Oliveira
    THYROID, 2016, 26 (03) : 414 - 419
12345